eprenetapopt + acalabrutinib OR (venetoclax + rituximab)

This entry refers to investigational combination regimens involving eprenetapopt with either acalabrutinib or the combination of venetoclax and rituximab, primarily studied in hematologic malignancies such as lymphoid cancers. Eprenetapopt (APR‑246) is a small molecule that reactivates mutant p53 protein, restoring its tumor suppressor function. Acalabrutinib is a Bruton tyrosine kinase inhibitor that blocks B-cell receptor signaling, used in various B-cell malignancies. Venetoclax is a selective BCL‑2 inhibitor promoting apoptosis in cancer cells dependent on this anti-apoptotic protein; it is often combined with the monoclonal antibody rituximab, which targets CD20 on B-cells to induce cell death. These combinations are under clinical investigation for their synergistic effects against resistant or relapsed hematologic cancers[4][8].

Brand names

Calquence (for acalabrutinib)Venclexta (for venetoclax)Rituxan (for rituximab)